Literature DB >> 27269232

Survival and Prognostic Factors of Colorectal Liver Metastases After Surgical and Nonsurgical Treatment.

Johannes Lemke1, Gregor Cammerer1, Johannes Ganser1, Jan Scheele1, Pengfei Xu1, Silvia Sander2, Doris Henne-Bruns1, Marko Kornmann3.   

Abstract

OBJECTIVE: Colorectal cancer is one leading cause of cancer-related death worldwide, and distant metastases determine an unfavorable prognosis. Surgical resection of colorectal liver metastases (CRLM) improves survival and provides the chance for cure. The aim of this study was to prospectively analyze the outcome of patients with CRLM in a population-based manner, and thereby, to compare the prognosis of patients undergoing resection with those receiving nonsurgical treatment. Moreover, we set out to identify and confirm important prognostic factors after resection of CRLM. PATIENTS AND METHODS: We analyzed the outcome of 506 patients diagnosed with CRLM in our institution from 1996 to 2011. Survival and the impact of clinical and pathologic factors were analyzed by univariate analysis. Important independent prognostic factors were analyzed by multivariate analysis.
RESULTS: The 5-year overall survival rate (5y-OSR) for patients receiving resection of CRLM (n = 152) was 46% (95% confidence interval (CI), 37%-54%) compared with a 5y-OSR of 6% (95% CI, 4%-9%) for patients treated nonsurgically (n = 354). There was no perioperative mortality. Multivariate analysis revealed, among other factors, good performance status of the patient (low American Society of Anesthesiologists score), the absence of extrahepatic metastases, < 5 metastatic lesions, and a tumor-free resection margin (R0) as important, independent prognostic factors. Importantly, repeated hepatic resections of CRLM performed in 13 patients were associated with an excellent outcome (5y-OSR, 47%; 95% CI, 17%-72%).
CONCLUSION: Surgical resection, which can be performed with tolerable site-effects, is the first choice for patients diagnosed with metachronous and synchronous CRLM. Of note, repeated resections should be advised in recurrent intrahepatic colorectal cancer whenever possible. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Liver metastases; Resection; Surgery; Survival

Mesh:

Year:  2016        PMID: 27269232     DOI: 10.1016/j.clcc.2016.04.007

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  7 in total

1.  Model-Based Computational Analysis on the Effectiveness of Enhanced Recovery after Surgery in the Operating Room with Nursing.

Authors:  Wenji Li; Shu Huang; Yong Xie; Guanyu Chen; Jun Yuan; Yun Yang
Journal:  Front Surg       Date:  2022-05-18

2.  Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Authors:  Shiraj Sen; Kenneth Hess; David S Hong; Aung Naing; Sarina Piha-Paul; Filip Janku; Siqing Fu; Ishwaria M Subbiah; Holly Liu; Rahil Khanji; Le Huang; Shhyam Moorthy; Daniel D Karp; Apostolia Tsimberidou; Funda Meric-Bernstam; Vivek Subbiah
Journal:  Br J Cancer       Date:  2018-02-20       Impact factor: 7.640

Review 3.  Stereotactic body radiotherapy using the CyberKnife® system in the treatment of patients with liver metastases: state of the art.

Authors:  Peter Ihnát; Eva Skácelíková; Milan Tesař; Igor Penka
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

4.  Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition.

Authors:  Jennie Engstrand; Cecilia Strömberg; Henrik Nilsson; Jacob Freedman; Eduard Jonas
Journal:  World J Surg Oncol       Date:  2019-12-26       Impact factor: 2.754

5.  Nomogram Incorporating Preoperative Testing Markers for the prediction of Early Recurrence for Colorectal Liver Metastases with Neoadjuvant Chemotherapy followed by Hepatectomy.

Authors:  Qichen Chen; Yizhou Zhang; Xingchen Li; Zhen Huang; Hong Zhao; Jianqiang Cai
Journal:  J Cancer       Date:  2022-03-14       Impact factor: 4.207

6.  RE-HEPATECTOMY MEANS MORE MORBIDITY? A MULTICENTRIC ANALYSIS.

Authors:  Luiza Basilio; Klaus Steinbrück; Reinaldo Fernandes; Marcelo D'Oliveira; Renato Cano; Hanna Vasconcelos; Daniel Barbosa; Marcelo Enne
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

Review 7.  Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review.

Authors:  Shuri Aoki; Hideomi Yamashita; Osamu Abe; Keiichi Nakagawa
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.